Literature DB >> 10582872

Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells.

M Del Poeta1, S F Chen, D Von Hoff, C C Dykstra, M C Wani, G Manikumar, J Heitman, M E Wall, J R Perfect.   

Abstract

The activities of a series of camptothecin and nitidine derivatives that might interact with topoisomerase I were compared against yeast and cancer cell lines. Our findings reveal that structural modifications to camptothecin derivatives have profound effects on the topoisomerase I-drug poison complex in cells. Although the water-soluble anticancer agents topotecan and irinotecan are less active than the original structure, camptothecin, other derivatives or analogs with substitutions that increase compound solubility have also increased antifungal activities. In fact, a water-soluble prodrug appears to penetrate into the cell and release its active form; the resulting effect in complex with Cryptococcus neoformans topoisomerase I is a fungicidal response and also potent antitumor activity. Some of the compounds that are not toxic to wild-type yeast cells are extremely toxic to the yeast cells when the C. neoformans topoisomerase I target is overexpressed. With the known antifungal mechanism of a camptothecin-topoisomerase I complex as a cellular poison, these findings indicate that drug entry may be extremely important for antifungal activity. Nitidine chloride exhibits antifungal activity against yeast cells through a mechanism(s) other than topoisomerase I and appears to be less active than camptothecin analogs against tumor cells. Finally, some camptothecin analogs exhibit synergistic antifungal activity against yeast cells in combination with amphotericin B in vitro. Our results suggest that camptothecin and/or nitidine derivatives can exhibit potent antifungal activity and that the activities of camptothecin derivatives with existing antifungal drugs may be synergistic against pathogenic fungi. These new compounds, which exhibit potent antitumor activities, will likely require further structural changes to find more selective activity against fungal versus mammalian cells to hold promise as a new class of antifungal agents.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10582872      PMCID: PMC89577          DOI: 10.1128/AAC.43.12.2862

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

1.  DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts.

Authors:  B C Giovanella; J S Stehlin; M E Wall; M C Wani; A W Nicholas; L F Liu; R Silber; M Potmesil
Journal:  Science       Date:  1989-11-24       Impact factor: 47.728

2.  Topoisomerase I is essential in Cryptococcus neoformans: role In pathobiology and as an antifungal target.

Authors:  M Del Poeta; D L Toffaletti; T H Rude; C C Dykstra; J Heitman; J R Perfect
Journal:  Genetics       Date:  1999-05       Impact factor: 4.562

3.  Vectors for constitutive and inducible gene expression in yeast.

Authors:  M Schena; D Picard; K R Yamamoto
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

4.  Fluconazole resistant candida in AIDS.

Authors:  R Fox; K R Neal; C L Leen; M E Ellis; B K Mandal
Journal:  J Infect       Date:  1991-03       Impact factor: 6.072

5.  The yeast gene ERG6 is required for normal membrane function but is not essential for biosynthesis of the cell-cycle-sparking sterol.

Authors:  R F Gaber; D M Copple; B K Kennedy; M Vidal; M Bard
Journal:  Mol Cell Biol       Date:  1989-08       Impact factor: 4.272

6.  DNA topoisomerase-targeting antitumor drugs can be studied in yeast.

Authors:  J Nitiss; J C Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

7.  Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin.

Authors:  W K Eng; L Faucette; R K Johnson; R Sternglanz
Journal:  Mol Pharmacol       Date:  1988-12       Impact factor: 4.436

8.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

9.  Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II.

Authors:  M Potmesil; Y H Hsiang; L F Liu; B Bank; H Grossberg; S Kirschenbaum; T J Forlenza; A Penziner; D Kanganis; T J Forlenzar
Journal:  Cancer Res       Date:  1988-06-15       Impact factor: 12.701

10.  A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae.

Authors:  R S Sikorski; P Hieter
Journal:  Genetics       Date:  1989-05       Impact factor: 4.562

View more
  18 in total

1.  Nitidine chloride induces apoptosis, cell cycle arrest, and synergistic cytotoxicity with doxorubicin in breast cancer cells.

Authors:  Mingjuan Sun; Ning Zhang; Xiaolong Wang; Chang Cai; Jinjing Cun; Yaming Li; Shangge Lv; Qifeng Yang
Journal:  Tumour Biol       Date:  2014-07-17

Review 2.  The antifungal pipeline: a reality check.

Authors:  John R Perfect
Journal:  Nat Rev Drug Discov       Date:  2017-05-12       Impact factor: 84.694

3.  Role of OCT2 and MATE1 in renal disposition and toxicity of nitidine chloride.

Authors:  L P Li; F F Song; Y Y Weng; X Yang; K Wang; H M Lei; J Ma; H Zhou; H D Jiang
Journal:  Br J Pharmacol       Date:  2016-07-09       Impact factor: 8.739

Review 4.  Perspectives on biologically active camptothecin derivatives.

Authors:  Ying-Qian Liu; Wen-Qun Li; Susan L Morris-Natschke; Keduo Qian; Liu Yang; Gao-Xiang Zhu; Xiao-Bing Wu; An-Liang Chen; Shao-Yong Zhang; Xiang Nan; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2015-03-21       Impact factor: 12.944

5.  Biological activities of nitidine, a potential anti-malarial lead compound.

Authors:  Jérome Bouquet; Marion Rivaud; Séverine Chevalley; Eric Deharo; Valérie Jullian; Alexis Valentin
Journal:  Malar J       Date:  2012-03-09       Impact factor: 2.979

6.  Novel agent nitidine chloride induces erythroid differentiation and apoptosis in CML cells through c-Myc-miRNAs axis.

Authors:  Na Liu; Peng Li; Shaolei Zang; Qiang Liu; Daoxin Ma; Xiulian Sun; Chunyan Ji
Journal:  PLoS One       Date:  2015-02-03       Impact factor: 3.240

7.  Nitidine chloride inhibits hepatic cancer growth via modulation of multiple signaling pathways.

Authors:  Jiumao Lin; Aling Shen; Hongwei Chen; Jun Liao; Teng Xu; Liya Liu; Jing Lin; Jun Peng
Journal:  BMC Cancer       Date:  2014-09-30       Impact factor: 4.430

8.  Homologous recombination and Mus81 promote replication completion in response to replication fork blockage.

Authors:  Benjamin Pardo; María Moriel-Carretero; Thibaud Vicat; Andrés Aguilera; Philippe Pasero
Journal:  EMBO Rep       Date:  2020-05-17       Impact factor: 8.807

Review 9.  Natural products targeting cancer cell dependency.

Authors:  Changxiang Shi; Eun Ju Yang; Shishi Tao; Guowen Ren; Pui Kei Mou; Joong Sup Shim
Journal:  J Antibiot (Tokyo)       Date:  2021-06-23       Impact factor: 2.649

10.  A novel approach for organelle-specific DNA damage targeting reveals different susceptibility of mitochondrial DNA to the anticancer drugs camptothecin and topotecan.

Authors:  M C Díaz de la Loza; R E Wellinger
Journal:  Nucleic Acids Res       Date:  2009-01-16       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.